Abstract
The presently ongoing pandemic of human SARS-CoV-2 infections (COVID-19) presents an enormous challenge in surveillance, vaccine and antiviral drug development. Here we report the synthesis of new bioactive quinoline-morpholine hybrid compounds and their virological evaluation, which proves pronounced cell culture-based inhibitory profile against SARS-CoV-2. Thus, selected quinoline compounds may suggest specific hit-to-lead development.
Keywords: SARS-CoV-2; antiviral drug assessment; cell culture-based infection models; morpholine-quinoline hybrids; quinoline compounds.
All Keywords
【저자키워드】 SARS-CoV-2, antiviral drug assessment, cell culture-based infection models, morpholine-quinoline hybrids, quinoline compounds., 【초록키워드】 COVID-19, Vaccine, pandemic, Infection, antiviral drug, Surveillance, Cell culture, synthesis, SARS-CoV-2 infections, compounds, Virological, Compound, quinoline, human SARS-CoV-2, inhibitory, Cell, morpholine, selected, 【제목키워드】 Model, profile, Compound, New,
【저자키워드】 SARS-CoV-2, antiviral drug assessment, cell culture-based infection models, morpholine-quinoline hybrids, quinoline compounds., 【초록키워드】 COVID-19, Vaccine, pandemic, Infection, antiviral drug, Surveillance, Cell culture, synthesis, SARS-CoV-2 infections, compounds, Virological, Compound, quinoline, human SARS-CoV-2, inhibitory, Cell, morpholine, selected, 【제목키워드】 Model, profile, Compound, New,
{{{ 추상적인 }}}
현재 진행 중인 인간 SARS-CoV-2 감염(COVID-19)의 대유행은 감시, 백신 및 항바이러스 약물 개발에 엄청난 도전을 제시합니다. 여기에서 우리는 SARS-CoV-2에 대한 뚜렷한 세포 배양 기반 억제 프로필을 증명하는 새로운 생리 활성 퀴놀린-모르폴린 하이브리드 화합물의 합성과 바이러스학적 평가를 보고합니다. 따라서 선택된 퀴놀린 화합물은 특정 히트-투-리드 개발을 제안할 수 있습니다.
{{ 키워드: }} SARS-CoV-2; 항바이러스 약물 평가; 세포 배양 기반 감염 모델; 모르폴린-퀴놀린 하이브리드; 퀴놀린 화합물.